EMA601, a novel humanized fab inhibits platelet glycoprotein VI with unprecedented potency and protects mice from arterial thrombosis and ischemic stroke

Stefano Navarro, Ph.D.
University of Wuerzburg
Wuerzburg, Germany

Bernhard Nieswandt, Ph.D.
University of Wuerzburg and Emfret Analytics GmbH
Wuerzburg, Germany; Eibelstadt Germany

First inhibitors of platelet GPVI recently passed clinical phase 1b/2a studies and proved to be well tolerated and safe. Stefano Navarro, Ph.D., and Bernhard Nieswandt, Ph.D., present the development of a novel humanized anti-GPVI antibody Fab-fragment (EMA601, kD: 0.195 nM) that inhibits hGPVI function with unprecedented potency in vitro and in vivo. Mouse model results of testing EMA601 and its parental murine variant (Emf6.1-Fab) will be presented. The team concluded in their work that EMA601 is a conceptually novel and promising antiplatelet agent to efficiently prevent or treat arterial thrombosis and thrombo-inflammatory pathologies in humans at risk.